Eloxx Pharmaceuticals (ELOX) 10-K 2016 FY Annual report

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Sevion Therapeutics, Inc. for the year ended June 30, 2016 as filed with the Securities and Exchange Commission on the date hereof, the undersigned, David Rector, Chief Executive Officer, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:

(1)          The Annual Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)          The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of Sevion Therapeutics, Inc.

Dated: October 13, 2016	/s/ David Rector *
	David Rector
	President and Chief Executive Officer
	(principal executive officer)

* A signed original of this written statement required by Section 906 has been provided to us and will be retained by us and furnished to the Securities and Exchange Commission or its staff upon request.